Plasmacure, a Dutch medical technology company, has raised €6 million (US$7 million) in series A funding to expand its Plasoma cold plasma system for treating complex wounds.

The round was led by US-based Venture Medical, LLC, with participation from Coöperatie VGZ, Noaber, Stichting Triade, and existing investors EIC Fund and Oost NL.

Venture Medical will also provide over US$10 million to support regulatory and reimbursement efforts for Plasoma in the US.

Plasoma targets chronic wounds such as diabetic foot ulcers, venous leg ulcers, and pressure ulcers.

A recent clinical trial showed it could close wounds up to 2.5 times more effectively than standard treatments.

The funding will support global rollout and adoption as aging populations and rising diabetes rates drive demand for advanced wound care.

🔗 Source: Plasmacure

🧠 Food for thought

1️⃣ Chronic wound care represents a massive but under-addressed market opportunity

The $6 million investment in Plasmacure reflects growing recognition of the economic burden of chronic wounds, which costs the U.S. healthcare system $45-55 billion annually1.

The global wound care market was valued at $18.51 billion in 2022 and is projected to grow to $30.04 billion by 2030, representing significant growth potential for effective treatment solutions1.

This economic opportunity is driven by demographic trends, as chronic wounds affect approximately 10.5 million U.S. Medicare beneficiaries (2.5% of the total U.S. population), with prevalence rising due to aging populations and increasing chronic disease rates2.

The U.S. wound care centers market specifically is expected to grow from $15.31 billion in 2024 to $25.27 billion by 2034, with a CAGR of 5.15%, demonstrating sustained long-term growth prospects in the specialized care segment3.

Despite these numbers, there remains a disparity in research funding for chronic wounds compared to other conditions with similar or lower mortality rates, indicating this remains an underserved market with room for innovative solutions1.

2️⃣ Technologies that accelerate healing demonstrate substantial cost-effectiveness potential

Plasmacure’s claim that PLASOMA can close up to 2.5 times more complex wounds than standard care aligns with research showing that improved healing technologies can deliver significant economic benefits beyond clinical outcomes.